Literature DB >> 23733462

Escherichia coli resistance to nonbiocidal antibiofilm polysaccharides is rare and mediated by multiple mutations leading to surface physicochemical modifications.

Laetitia Travier1, Olaya Rendueles, Lionel Ferrières, Jean-Marie Herry, Jean-Marc Ghigo.   

Abstract

Antivirulence strategies targeting bacterial behavior, such as adhesion and biofilm formation, are expected to exert low selective pressure and have been proposed as alternatives to biocidal antibiotic treatments to avoid the rapid occurrence of bacterial resistance. Here, we tested this hypothesis using group 2 capsule polysaccharide (G2cps), a polysaccharidic molecule previously shown to impair bacterium-surface interactions, and we investigated the nature of bacterial resistance to a nonbiocidal antibiofilm strategy. We screened an Escherichia coli mutant library for an increased ability to form biofilm in the presence of G2cps, and we identified several mutants displaying partial but not total resistance to this antibiofilm polysaccharide. Our genetic analysis showed that partial resistance to G2cps results from multiple unrelated mutations leading to modifications in surface physicochemical properties that counteract the changes in ionic charge and Lewis base properties induced by G2cps. Moreover, some of the identified mutants harboring improved biofilm formation in the presence of G2cps were also partially resistant to other antibiofilm molecules. This study therefore shows that alterations of bacterial surface properties mediate only partial resistance to G2cps. It also experimentally validates the potential value of nonbiocidal antibiofilm strategies, since full resistance to antibiofilm compounds is rare and potentially unlikely to arise in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23733462      PMCID: PMC3719787          DOI: 10.1128/AAC.02606-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  60 in total

1.  Production of resistant HIV mutants during antiretroviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  A colorimetric method for the determination of sugars.

Authors:  M DUBOIS; K GILLES; J K HAMILTON; P A REBERS; F SMITH
Journal:  Nature       Date:  1951-07-28       Impact factor: 49.962

3.  Genetic reconstitution of the high-affinity L-arabinose transport system.

Authors:  B F Horazdovsky; R W Hogg
Journal:  J Bacteriol       Date:  1989-06       Impact factor: 3.490

Review 4.  Anti-virulence strategies to combat bacteria-mediated disease.

Authors:  David A Rasko; Vanessa Sperandio
Journal:  Nat Rev Drug Discov       Date:  2010-01-18       Impact factor: 84.694

Review 5.  Antibacterial surfaces for biomedical devices.

Authors:  Krasimir Vasilev; Jessica Cook; Hans J Griesser
Journal:  Expert Rev Med Devices       Date:  2009-09       Impact factor: 3.166

6.  Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression.

Authors:  Gabriel Mitchell; Myriame Lafrance; Simon Boulanger; David Lalonde Séguin; Isabelle Guay; Mariza Gattuso; Eric Marsault; Kamal Bouarab; François Malouin
Journal:  J Antimicrob Chemother       Date:  2011-11-30       Impact factor: 5.790

7.  The putative response regulator BaeR stimulates multidrug resistance of Escherichia coli via a novel multidrug exporter system, MdtABC.

Authors:  Satoshi Nagakubo; Kunihiko Nishino; Takahiro Hirata; Akihito Yamaguchi
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

8.  Direct evidence for coupling between bacterial chemoreceptors.

Authors:  Ady Vaknin; Howard C Berg
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

9.  Screening of Escherichia coli species biodiversity reveals new biofilm-associated antiadhesion polysaccharides.

Authors:  Olaya Rendueles; Laetitia Travier; Patricia Latour-Lambert; Thierry Fontaine; Julie Magnus; Erick Denamur; Jean-Marc Ghigo
Journal:  MBio       Date:  2011-05-10       Impact factor: 7.867

10.  Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin.

Authors:  Steve P Bernier; David Lebeaux; Alicia S DeFrancesco; Amandine Valomon; Guillaume Soubigou; Jean-Yves Coppée; Jean-Marc Ghigo; Christophe Beloin
Journal:  PLoS Genet       Date:  2013-01-03       Impact factor: 5.917

View more
  6 in total

Review 1.  Resistance to quorum-quenching compounds.

Authors:  Rodolfo García-Contreras; Toshinari Maeda; Thomas K Wood
Journal:  Appl Environ Microbiol       Date:  2013-09-06       Impact factor: 4.792

Review 2.  Novel Treatment Strategies for Biofilm-Based Infections.

Authors:  Claudia Vuotto; Gianfranco Donelli
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

3.  'Evolution-proofing' antibacterials.

Authors:  Adin Ross-Gillespie; Rolf Kümmerli
Journal:  Evol Med Public Health       Date:  2014-08-13

4.  Capsicumicine, a New Bioinspired Peptide from Red Peppers Prevents Staphylococcal Biofilm In Vitro and In Vivo via a Matrix Anti-Assembly Mechanism of Action.

Authors:  Rafael Gomes Von Borowski; Sophie Chat; Rafael Schneider; Sylvie Nonin-Lecomte; Serge Bouaziz; Emmanuel Giudice; Aline Rigon Zimmer; Simone Cristina Baggio Gnoatto; Alexandre José Macedo; Reynald Gillet
Journal:  Microbiol Spectr       Date:  2021-10-27

5.  Anti-biofilm activity: a function of Klebsiella pneumoniae capsular polysaccharide.

Authors:  Marina Dos Santos Goncalves; Cédric Delattre; Damien Balestrino; Nicolas Charbonnel; Redouan Elboutachfaiti; Anne Wadouachi; Stéphanie Badel; Thierry Bernardi; Philippe Michaud; Christiane Forestier
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

6.  Antimicrobial peptides properties beyond growth inhibition and bacterial killing.

Authors:  Israel Castillo-Juárez; Blanca Esther Blancas-Luciano; Rodolfo García-Contreras; Ana María Fernández-Presas
Journal:  PeerJ       Date:  2022-01-21       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.